CND Life Sciences

About:

CND Life Sciences develops an evidence-based tool to help confirm a diagnosis of synucleinopathy.

Website: https://cndlifesciences.com/

Top Investors: Michael J. Fox Foundation, National Institute on Aging, National Institute of Neurological Disorders and Stroke, HonorHealth, Cambrian Capital Partners

Description:

CND Life Sciences develops an evidence-based tool to help confirm a diagnosis of synucleinopathy. It has launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid in the confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).